Advanced Medical Solutions Group (CHIX:AMSL) Net-Net Working Capital: £-0.25 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMSL Advanced Medical Solutions Group PLC CHIX:AMSL
92 GF Score
Price £2.80
GF Value £3.71
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Advanced Medical Solutions Group Net-Net Working Capital?

Advanced Medical Solutions Group CHIX:AMSL 92 Net-Net Working Capital is £-0.25 as of Dec. 2025. GuruFocus rates CHIX:AMSL with a GF Score™ of 92/100 and a GF Value™ of £3.71 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 425 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 235293.88% on this metric.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Advanced Medical Solutions Group's Net-Net Working Capital for the quarter that ended in Dec. 2025 was £-0.25.

The industry rank for Advanced Medical Solutions Group's Net-Net Working Capital or its related term are showing as below:

CHIX:AMSl's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.8
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Advanced Medical Solutions Group  (CHIX:AMSl) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Advanced Medical Solutions Group Net-Net Working Capital Related Terms


Advanced Medical Solutions Group Net-Net Working Capital Historical Data

* Premium members only.

The historical data trend for Advanced Medical Solutions Group's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Medical Solutions Group Net-Net Working Capital Chart

Advanced Medical Solutions Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.30 0.23 -0.32 -0.25

Advanced Medical Solutions Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.24 -0.32 -0.25 -0.25

CHIX:AMSL vs ISRG, BDX, MDLN: Net-Net Working Capital Comparison

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Price-to-Net-Net-Working-Capital falls into.


CHIX:AMSL
92GF Score
Advanced Medical Solutions Group PLC CHIX:AMSL
Net-Net Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Medical Solutions Group Net-Net Working Capital Calculation

Advanced Medical Solutions Group's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2025 is calculated as

Net-Net Working Capital(A: Dec. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(18.015+0.75 * 38.456+0.5 * 70.047-134.666
-0-1.313)/216.404
=-0.25

Advanced Medical Solutions Group's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2025 is calculated as

Net-Net Working Capital(Q: Dec. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(18.015+0.75 * 38.456+0.5 * 70.047-134.666
-0-1.313)/216.404
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

What does a Net-Net Working Capital of £-0.25 mean?
Advanced Medical Solutions Group (CHIX:AMSL) has a Net-Net Working Capital of £-0.25 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Advanced Medical Solutions Group According to the industry distribution chart, Advanced Medical Solutions Group ranks #999999 out of 425 companies in the Medical Devices & Instruments industry.
Is Advanced Medical Solutions Group's Net-Net Working Capital too high?
Advanced Medical Solutions Group's current Net-Net Working Capital is £-0.25. Based on the distribution chart, Advanced Medical Solutions Group ranks #999999 out of 425 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Advanced Medical Solutions Group has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Net-Net Working Capital compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #999999 out of 425 companies for Net-Net Working Capital. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Net-Net Working Capital is 6.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.80, based on 425 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Advanced Medical Solutions Group For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Net-Net Working Capital is £-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.71, compared to a current price of £2.80 — trading 24.7% below its estimated fair value. The current Net-Net Working Capital is £-0.25. Advanced Medical Solutions Group's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Net-Net Working Capital is £-0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued. The current stock price of £2.80 is trading 24.7% below its estimated GF Value™ of £3.71. GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.

Key valuation signals for CHIX:AMSL:

  • Net-Net Working Capital: £-0.25
  • GF Value™: £3.71 vs. price of £2.80 (24.7% below fair value)
  • GF Score™: 92/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Advanced Medical Solutions Group Business Description

Other Exchanges AMS:UKAQA:Germany
Address Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
92GF Score

Get the complete analysis for CHIX:AMSL

Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.80
Price
£3.71
GF Value